KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Regeneron Pharmaceuticals (REGN) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to 21.96%.

  • Regeneron Pharmaceuticals' EBITDA Margin fell 4600.0% to 21.96% in Q4 2025 from the same period last year, while for Dec 2025 it was 32.0%, marking a year-over-year increase of 4200.0%. This contributed to the annual value of 32.0% for FY2025, which is 4200.0% up from last year.
  • According to the latest figures from Q4 2025, Regeneron Pharmaceuticals' EBITDA Margin is 21.96%, which was down 4600.0% from 39.33% recorded in Q3 2025.
  • In the past 5 years, Regeneron Pharmaceuticals' EBITDA Margin ranged from a high of 1659.2% in Q1 2022 and a low of 21.96% during Q4 2025
  • For the 5-year period, Regeneron Pharmaceuticals' EBITDA Margin averaged around 176.86%, with its median value being 38.91% (2025).
  • Its EBITDA Margin has fluctuated over the past 5 years, first skyrocketed by 16156200bps in 2022, then crashed by -16315300bps in 2023.
  • Regeneron Pharmaceuticals' EBITDA Margin (Quarter) stood at 44.29% in 2021, then surged by 2685bps to 1233.4% in 2022, then tumbled by -97bps to 36.56% in 2023, then tumbled by -39bps to 22.42% in 2024, then fell by -2bps to 21.96% in 2025.
  • Its EBITDA Margin was 21.96% in Q4 2025, compared to 39.33% in Q3 2025 and 38.5% in Q2 2025.